CL (Cutaneous leishmaniasis) is a parasitic infection caused due to parasite named Leishmania. CL incidents have augmented radically in Syria and neighboring nations owing to conflict-associated dislocation of Syrians. A research posted by Rana El Hajj in PLOS Neglected Tropical Diseases at the American University of Beirut defines the growth of a new immunomodulatory analog that might be an effectual cure of CL.
Presently employed treatments against CL might result in complete or partial cure. On the other hand, they relate with many restrictions, comprising lack of availability, recurring painful injections, emergence of resistant strains, and expensive cost. In addition to this, their effectiveness stays limited by the patient’s immune system and age. Scientists examined the pre-clinical effectiveness of Imiquimod (an immunomodulatory drug) and EAPB0503 (one of its peers) on two strains (Leishmania tropica and Leishmania major) responsible for CL in the Middle East region. They also experimented these drugs on newly isolated parasites from biopsies of patients and proved their leishmanicidal strength.
On a related note, a study by UT Southwestern on mice offers new hints about how a category of anti-refusal drugs employed after transplants of organ might also slow the development of early-phase Alzheimer’s illness.
Alzheimer’s, a growing type of dementia, impacts an anticipated 5 Million individuals in the U.S. This is a number anticipated to almost increase 3x by 2050. Even though Alzheimer’s normally strikes post the age of 65, alterations in the brain can start years prior to the symptoms start appearing, as per the Centers for Disease Control and Prevention.
The scientists researched how the links between neurons (synapses) are broken early during the disease taking place. This brakeage in link probably causes the memory and behavioral changes that take place as the disease grows, claimed corresponding author of the Science Signaling research and Chairman of Pathology, Dr. James Malter, to the media in an interview.